Illumina, Inc. (ILMN) Financials
ILMN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 6.7 billion | 3.8 billion |
| March 31, 2026 | 6.6 billion | 3.9 billion |
| Dec. 31, 2025 | 6.6 billion | 3.9 billion |
| Sept. 30, 2025 | 6.2 billion | 3.8 billion |
ILMN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 161.0 million | -60.0 million |
| March 31, 2026 | 251.0 million | 60.0 million |
| Dec. 31, 2025 | 267.0 million | 63.0 million |
| Sept. 30, 2025 | 260.0 million | 70.0 million |
ILMN Net Income
No data available :(
ILMN Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 1.2 billion | 1.5 billion | 536.0 million |
| March 31, 2026 | 1.2 billion | 1.5 billion | 555.0 million |
| Dec. 31, 2025 | 1.6 billion | 1.5 billion | 564.0 million |
| Sept. 30, 2025 | 1.3 billion | 994.0 million | 506.0 million |
ILMN Shares Outstanding
ILMN Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 40.0 million | 252.0 million | 273.0 million | - |
| March 31, 2026 | 38.0 million | 240.0 million | 272.0 million | - |
| Dec. 31, 2025 | 54.0 million | 238.0 million | 283.0 million | - |
| Sept. 30, 2025 | 24.0 million | 228.0 million | 273.0 million | - |
ILMN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 1.2 billion | 389.0 million |
| March 31, 2026 | 1.1 billion | 370.0 million |
| Dec. 31, 2025 | 1.2 billion | 382.0 million |
| Sept. 30, 2025 | 1.1 billion | 351.0 million |
ILMN Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ILMN
Price: $269.42
52 week price:
Payout Ratio Range:
Earnings Per Share: 5.36 USD
P/E Ratio: 37.29
Exchange: NMS
Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Volume: 1.1 million
Ebitda: 273.0 millionMarket Capitalization: 40.5 billion